Found 556472 clinical trials
Sort by:
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Not Applicable
Not yet recruiting
- Conditions
- Prostate Cancer (CRPC)Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- ARTBIO Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT07214961
- Locations
- 🇺🇸
BAMF Health, Grand Rapids, Michigan, United States
🇺🇸Washington University, St Louis, Missouri, United States
🇺🇸XCancer, 17607 Gold Plaza, Omaha, Nebraska, United States
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
Not Applicable
Not yet recruiting
- Conditions
- Prosthetic-joint Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Peptilogics
- Target Recruit Count
- 240
- Registration Number
- NCT07214311
Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings
Not Applicable
- Conditions
- Mobility ImpairmentClinical Workflow OptimizationSanitation Protocol ComplianceESG-linked Healthcare Robotics Deployment
- Interventions
- Biological: Skin Cell DipBiological: Stem Cell DipBehavioral: ESG Compliance Monitoring, Operational protocolOther: Wage Token Distribution
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Truway Health, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT07214896
- Locations
- 🇺🇸
Truway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016, New York, New York, United States
🇺🇸Coalition Retrofit Clinic - Austin, TX, Austin, Texas, United States
🇩🇪ESG Compliance Lab, Frankfurt, Germany
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
Not Applicable
Not yet recruiting
- Conditions
- Bipolar I DisorderBipolar II DisorderSchizo Affective DisorderObesityWeight LossGLP - 1
- Interventions
- Behavioral: Group Therapy ProgramDrug: naltrexone and bupropion (combination)Drug: Phentermine-Topiramate
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 100
- Registration Number
- NCT07213466
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Intervention for Alcohol Use Disorder Recovery After Liver Transplantation
Not Applicable
Not yet recruiting
- Conditions
- Liver Transplant RecipientAlcohol Use Disorders (AUD)
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Leigh Anne Dageforde
- Target Recruit Count
- 40
- Registration Number
- NCT07214259
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Dermabrasion in Mohs: Split-Scar Trial
Not Applicable
Not yet recruiting
- Conditions
- Wound Heal
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 50
- Registration Number
- NCT07213921
- Locations
- 🇺🇸
UW Health Mohs Surgery Clinic, Madison, Wisconsin, United States
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Not Applicable
Not yet recruiting
- Conditions
- Ovarian Cancer
- Interventions
- Drug: Investigator's choice of chemotherapy
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 466
- Registration Number
- NCT07214779
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
Not Applicable
Not yet recruiting
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Drug: standard second line treatment, at discretion of the investigator
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 60
- Registration Number
- NCT07213570
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
Not Applicable
Not yet recruiting
- Conditions
- Fatty Liver Disease
- Interventions
- Drug: NNC4005-001Drug: Placebo
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT07214870
- Locations
- 🇨🇦
Altasciences, Montreal, Quebec, Canada
Harmonized Healing: Personalized Music Interventions to Address Chronic Pain in People Living With HIV
Not Applicable
Not yet recruiting
- Conditions
- Chronic PainHiv
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT07214077